Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2554329 | 0.78 | SLC2A1 (0.43) | SMN1; SMN2SOS1KMT2ANPC1RAB9A | |
| SCHEMBL3279463 | 0.78 | GRM5 (0.44) | GRM5SMN1; SMN2KMT2A | |
| SCHEMBL10886727 | 0.78 | VCP (0.38) | GRM5TDP1NPC1RAB9A | |
| SCHEMBL2552386 | 0.78 | SLC2A1 (0.35) | GRM5FFAR1FFAR4TDP1 | |
| SCHEMBL6743389 | 0.78 | KDM4E (0.41) | — | |
| SCHEMBL1044275 | 0.78 | HDAC1 (0.41) | GRM5FFAR1FFAR4KMT2ANPC1 | |
| SCHEMBL2140487 | 0.75 | KIF11 (0.41) | — | |
| SCHEMBL3035956 | 0.75 | MAPT (0.35) | SMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL22031496 | 0.75 | EGFR (0.31) | — | |
| SCHEMBL22031515 | 0.75 | TRPV4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102898330-B | Colchicine derivatives | UNIV ZHEJIANG | 2015-02-25 | — | — | CN | claimed |
| CN-104230937-A | Colchicine derivative | UNIV ZHEJIANG | 2014-12-24 | — | — | CN | claimed |
| US-8034936-B2 | Spirocyclic cyclohexane compounds useful to treat substance dependency | GRUENENTHAL GMBH (DE) | 2011-10-11 | — | — | US | claimed |
| US-7932264-B2 | Sinomenine derivatives and preparation and uses thereof | NATUREMED GROUP CORPORATION (US) | 2011-04-26 | — | — | US | claimed |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2011-03-03 | — | — | US | claimed |
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOTICS, INC. | 2009-01-29 | — | — | US | claimed |
| US-7452996-B2 | Substituted quinoline derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-18 | — | — | US | claimed |
| EP-1753723-B1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-08-13 | — | — | EP | claimed |
| CN-100408578-C | A class of 17-acyl diversine derivatives and its preparing method | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2008-08-06 | — | — | CN | claimed |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-30 | — | — | US | claimed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | claimed |
| EP-1212302-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| US-6388081-B1 | 4-substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries | LION BIOSCIENCE AG (DE) | 2002-05-14 | — | — | US | claimed |
| US-6262269-B1 | 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries | TREGA BIOSCIENCES, INC. | 2001-07-17 | — | — | US | claimed |
| WO-2001019808-A1 | CHEMICAL COMPOUNDS AND COMPOSITIONS AND THEIR USE AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| WO-2001019796-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| EP-0983507-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | Trega Biosciences, Inc. (US) | 2000-03-08 | — | — | EP | claimed |
| EP-0977989-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | ABCG2, ABCB1, UGT2B7 | GRM5 1336/4885CES2 149/4885CES1 452/4885 |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSE | GRM5 4831/4885CES2 458/4885CES1 173/4885 |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | TACR2, OPRK1, OPRD1 | GRM5 246/4885CES2 9/4885CES1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.